Table 3.
Significantly enriched pathways during PG(Q-value < 0.05).
| Pathway | DEGs with pathway annotation (620) | All genes with pathway annotation (22,673) | P-value | Q-value | KEGG Pathway ID | |
|---|---|---|---|---|---|---|
| 1 | ErbB signaling pathway | 13 (2.1%) | 85 (0.37%) | 5.13E-07 | 9.35686E-05 | ko04012 |
| 2 | TGF-β signaling pathway | 13 (2.1%) | 90 (0.4%) | 1.01E-06 | 9.35686E-05 | ko04350 |
| 3 | mTOR signaling pathway | 13 (2.1%) | 103 (0.45%) | 4.74E-06 | 0.00029372 | ko04150 |
| 4 | Dorso-ventral axis formation | 11 (1.77%) | 85 (0.37%) | 2.00E-05 | 0.000822388 | ko04320 |
| 5 | Natural killer cell mediated cytotoxicity | 11 (1.77%) | 86 (0.38%) | 2.23E-05 | 0.000822388 | ko04650 |
| 6 | MAPK signaling pathway | 22 (3.55%) | 299 (1.32%) | 2.84E-05 | 0.000822388 | ko04010 |
| 7 | Long-term depression | 11 (1.77%) | 89 (0.39%) | 3.10E-05 | 0.000822388 | ko04730 |
| 8 | Focal adhesion | 17 (2.74%) | 203 (0.9%) | 4.62E-05 | 0.000942361 | ko04510 |
| 9 | T cell receptor signaling pathway | 11 (1.77%) | 93 (0.41%) | 4.68E-05 | 0.000942361 | ko04660 |
| 10 | GnRH signaling pathway | 16 (2.58%) | 185 (0.82%) | 5.21E-05 | 0.000942361 | ko04912 |
| 11 | MAPK signaling pathway–fly | 7 (1.13%) | 37 (0.16%) | 5.57E-05 | 0.000942361 | ko04013 |
| 12 | Non-small cell lung cancer | 10 (1.61%) | 80 (0.35%) | 6.40E-05 | 0.000992421 | ko05223 |
| 13 | Renal cell carcinoma | 10 (1.61%) | 84 (0.37%) | 9.74E-05 | 0.001393244 | ko05211 |
| 14 | Acute myeloid leukemia | 9 (1.45%) | 70 (0.31%) | 0.000118662 | 0.001576505 | ko05221 |
| 15 | Pathways in cancer | 20 (3.23%) | 290 (1.28%) | 0.000156568 | 0.001941443 | ko05200 |
| 16 | Thyroid cancer | 8 (1.29%) | 58 (0.26%) | 0.000171678 | 0.001995759 | ko05216 |
| 17 | Prostate cancer | 13 (2.1%) | 147 (0.65%) | 0.000206339 | 0.002257594 | ko05215 |
| 18 | Gap junction | 11 (1.77%) | 113 (0.5%) | 0.000273245 | 0.002823531 | ko04540 |
| 19 | VEGF signaling pathway | 11 (1.77%) | 114 (0.5%) | 0.000295107 | 0.002888943 | ko04370 |
| 20 | Insulin signaling pathway | 19 (3.06%) | 294 (1.3%) | 0.000509545 | 0.004738766 | ko04910 |
| 21 | Phosphatidylinositol signaling system | 17 (2.74%) | 253 (1.12%) | 0.000639121 | 0.005660788 | ko04070 |
| 22 | Long-term potentiation | 14 (2.26%) | 188 (0.83%) | 0.000695286 | 0.005878324 | ko04720 |
| 23 | Tight junction | 18 (2.9%) | 285 (1.26%) | 0.000922378 | 0.007459228 | ko04530 |
| 24 | Type II diabetes mellitus | 7 (1.13%) | 62 (0.27%) | 0.001477238 | 0.011448595 | ko04930 |
| 25 | Chemokine signaling pathway | 9 (1.45%) | 101 (0.45%) | 0.001805983 | 0.013436514 | ko04062 |
| 26 | Melanogenesis | 13 (2.1%) | 189 (0.83%) | 0.002173863 | 0.015551482 | ko04916 |
| 27 | Sphingolipid metabolism | 8 (1.29%) | 85 (0.37%) | 0.002266143 | 0.015611207 | ko00600 |
| 28 | Fc ε RI signaling pathway | 7 (1.13%) | 70 (0.31%) | 0.002986459 | 0.019101208 | ko04664 |
| 29 | B cell receptor signaling pathway | 8 (1.29%) | 89 (0.39%) | 0.003025235 | 0.019101208 | ko04662 |
| 30 | Regulation of actin cytoskeleton | 15 (2.42%) | 244 (1.08%) | 0.00308084 | 0.019101208 | ko04810 |
| 31 | Endometrial cancer | 8 (1.29%) | 92 (0.41%) | 0.003714169 | 0.022285014 | ko05213 |
| 32 | Inositol phosphate metabolism | 12 (1.94%) | 179 (0.79%) | 0.003895542 | 0.022642838 | ko00562 |
| 33 | Glioma | 12 (1.94%) | 182 (0.8%) | 0.004448137 | 0.025071318 | ko05214 |
| 34 | Chronic myeloid leukemia | 7 (1.13%) | 76 (0.34%) | 0.004735616 | 0.025906605 | ko05220 |
| 35 | Axon guidance | 8 (1.29%) | 98 (0.43%) | 0.005450439 | 0.028160602 | ko04360 |
| 36 | Colorectal cancer | 8 (1.29%) | 98 (0.43%) | 0.005450439 | 0.028160602 | ko05210 |
| 37 | Wnt signaling pathway | 13 (2.1%) | 215 (0.95%) | 0.006467202 | 0.031924369 | ko04310 |
| 38 | Adherens junction | 8 (1.29%) | 101 (0.45%) | 0.006522183 | 0.031924369 | ko04520 |
| 39 | Vascular smooth muscle contraction | 12 (1.94%) | 192 (0.85%) | 0.006757216 | 0.032226723 | ko04270 |
| 40 | Melanoma | 7 (1.13%) | 82 (0.36%) | 0.007163473 | 0.032497707 | ko05218 |
| 41 | Bladder cancer | 7 (1.13%) | 82 (0.36%) | 0.007163473 | 0.032497707 | ko05219 |
| 42 | Vibrio cholerae infection | 8 (1.29%) | 105 (0.46%) | 0.008190482 | 0.036144692 | ko05110 |
| 43 | Progesterone-mediated oocyte maturation | 10 (1.61%) | 150 (0.66%) | 0.008356031 | 0.036144692 | ko04914 |